Open AccessEfficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity
Author(s) -
Punzi Henry,
Shojaee Ali,
Waverczak William F.,
Maa JenFue
Publication year - 2011
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2010.00422.x
Subject(s) - medicine , olmesartan , amlodipine , ambulatory , ambulatory blood pressure , diabetes mellitus , blood pressure , type 2 diabetes , urology , obesity , endocrinology
A subgroup analysis of a prospective, open‐label, single‐arm titration study in patients with hypertension and type 2 diabetes or obesity is reported. The primary end point was the change from baseline in mean 24‐hour ambulatory systolic blood pressure (BP) after 12 weeks. Patients received amlodipine 5 mg/d and were uptitrated (if seated [Se] BP was ≥120/80 mm Hg) at 3‐week intervals to amlodipine/olmesartan medoxomil 5/20 mg/d, 5/40 mg/d, and 10/40 mg/d. In patients with diabetes and obesity, baseline 24‐hour ambulatory BP (±standard deviation) was 145.6±10.4/83.1±9.0 mm Hg and 143.7±9.8/84.9±8.2 mm Hg, respectively, and baseline SeBP was 159.1±11.3/90.3±9.2 mm Hg and 158.2±12.5/94.2±8.5 mm Hg, respectively. Changes from baseline in mean 24‐hour ambulatory BP (±standard error of the mean) were −21.5±1.8/−12.6±1.1 mm Hg and 21.6±1.1/13.4±0.8 mm Hg in patients with diabetes and obesity, respectively. Prespecified 24‐hour ambulatory BP targets of <130/80 mm Hg, <125/75 mm Hg, and <120/80 mm Hg were achieved by 79.1%, 53.5%, and 39.5% of patients with diabetes and 75.3%, 58.4%, and 43.8% of obese patients, respectively. The SeBP goal of <130/80 mm Hg was achieved by 26.1% of patients with diabetes and <140/90 mm Hg was achieved by 78.1% of obese patients. J Clin Hypertens (Greenwich) . 2011;13:422–430. ©2011 Wiley Periodicals, Inc.